P. Harvey

发表

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

N. Pryer, D. W. Fry, W. Elliott, 2004, Molecular cancer therapeutics.

The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activities

J. Domagala, D. Hupe, Y. Song, 1997, Antimicrobial agents and chemotherapy.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

D. W. Fry, D. Mcnamara, Hairong Zhou, 2005, Journal of medicinal chemistry.

A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2,2'-dithiobisbenzamides.

J. Domagala, D. Hupe, R. Schultz, 1997, Bioorganic & medicinal chemistry.

The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity.

J. Domagala, D. Hupe, P. Harvey, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

P. Ellis, W. Denny, A. Bridges, 2006, Journal of medicinal chemistry.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

D. W. Fry, W. Elliott, D. Mcnamara, 2005, Journal of medicinal chemistry.

2,2′-dithiobisbenzamides derived from α-, β- and γ-amino acids possessing anti-HIV activities: synthesis and structure–activity relationship

D. P. Mack, W. J. Turner, J. Domagala, 1998 .

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

D. Boschelli, D. W. Fry, S. Trumpp-Kallmeyer, 2000, Journal of medicinal chemistry.

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.

J. A. Spicer, P. Ellis, W. Denny, 2016, Journal of medicinal chemistry.

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

P. Ellis, A. Bridges, D. W. Fry, 2008, Molecular Cancer Therapeutics.

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Pyrido[2,3-d]pyrimidin-7-one Inhi-bitors of Cyclin-Dependent Kinases.

D. Boschelli, S. Trumpp-Kallmeyer, D. Mcnamara, 2001 .